[1] Allen RA, Lisa JR. Combined liver cell and bile duct carcinoma. Am J Pathol, 1949, 25: 647-655.
[2] Wang A, Wu L, Lin J, et al. Whole-exome sequencing reveals the origin and evolution of hepato-cholangiocarcinoma. Nat Commun, 2018, 9: 894.
[3] Beaufrère A, Calderaro J, Paradis V. Combined hepatocellular-cholangiocarcinoma: An update. J Hepatol, 2021, 74: 1212-1224.
[4] Chen X, Lu Y, Shi X, et al. Morbidity, prognostic factors, and competing risk nomogram for combined hepatocellular-cholangiocarcinoma. J Oncol, 2021, 2021: 3002480.
[5] Ramai D, Ofosu A, Lai JK, et al. Combined hepatocellular cholangiocarcinoma: A population-based retrospective study. Am J Gastroenterol, 2019, 114: 1496-1501.
[6] Zhou YM, Zhang XF, Wu LP, et al. Risk factors for combined hepatocellular-cholangiocarcinoma: a hospital-based case-control study. World J Gastroenterol, 2014, 20: 12615-12620.
[7] Xue R, Chen L, Zhang C, et al. Genomic and transcriptomic profiling of combined hepatocellular and intrahepatic cholangiocarcinoma reveals distinct molecular subtypes. Cancer Cell, 2019, 35: 932-947 e8.
[8] Kim TH, Kim H, Joo I, et al. Combined hepatocellular-cholangiocarcinoma: changes in the 2019 world health organization histological classification system and potential impact on imaging-based diagnosis. Korean J Radiol, 2020, 21: 1115-1125.
[9] Zhang F, Chen XP, Zhang W, et al. Combined hepatocellular cholangiocarcinoma originating from hepatic progenitor cells: immunohistochemical and double-fluorescence immunostaining evidence. Histopathology, 2008, 52: 224-232.
[10] Liu Y, Xin B, Yamamoto M, et al. Generation of combined hepatocellular-cholangiocarcinoma through transdifferentiation and dedifferentiation in p53-knockout mice. Cancer Sci, 2021, 112: 3111-3124.
[11] Fujii H, Zhu XG, Matsumoto T, et al. Genetic classification of combined hepatocellular-cholangiocarcinoma. Hum Pathol, 2000, 31: 1011-1017.
[12] Goodman ZD, Ishak KG, Langloss JM, et al. Combined hepatocellular-cholangiocarcinoma. A histologic and immunohistochemical study. Cancer, 1985, 55: 124-135.
[13] Beaufrère ACJ, Paradis V. Combined hepatocellular-cholangiocarcinoma: An update.. J Hepatol, 2021, 74.
[14] Yin X ZB, Qiu SJ. Combined hepatocellular carcinoma and cholangiocarcinoma: clinical features, treatment modalities, and prognosis. Ann Surg Oncol, 2012, 19: 2869-2876.
[15] Lee CC, Wu CY, Chen J T, et al. Comparing combined hepatocellular-cholangiocarcinoma and cholangiocarcinoma: a clinicopathological study. Hepatogastroenterology, 2002, 49: 1487-1490.
[16] Fukukura Y, Taguchi J, Nakashima O, et al. Combined hepatocellular and cholangiocarcinoma: correlation between CT findings and clinicopathological features. J Comput Assist Tomogr, 1997, 21: 52-58.
[17] De campos RO, Semelka RC, Azevedo RM, et al. Combined hepatocellular carcinoma-cholangiocarcinoma: report of MR appearance in eleven patients. J Magn Reson Imaging, 2012, 36: 1139-1147.
[18] Granata V, Fusco R, Venanzio setola S, et al. Major and ancillary features according to LI-RADS in the assessment of combined hepatocellular-cholangiocarcinoma. Radiol Oncol, 2020, 54: 149-158.
[19] Yang J, Zhang YH, Li JW, et al. Contrast-enhanced ultrasound in association with serum biomarkers for differentiating combined hepatocellular-cholangiocarcinoma from hepatocellular carcinoma and intrahepatic cholangiocarcinoma. World J Gastroenterol, 2020, 26: 7325-7337.
[20] Brunt E, Aishima S, Clavien PA, et al. cHCC-CCA: Consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentation. Hepatology, 2018, 68: 113-126.
[21] Nakamura SSS, Sakaguchi T. Surgical treatment of patients with mixed hepatocellular carcinoma and cholangiocarcinoma. Cancer, 1996, 78: 1671-1676.
[22] La D, PV N T, V A, et al. Multi-center analysis of liver transplantation for combined hepatocellular carcinoma-cholangiocarcinoma liver tumors. J Am Coll Surg, 2021, 232: 361-371.
[23] Sapisochin G, Javle M, Lerut J, et al. Liver transplantation for cholangiocarcinoma and mixed hepatocellular cholangiocarcinoma: working group report from the ilts transplant oncology consensus conference. Transplantation, 2020, 104: 1125-1130.
[24] Magistri P, Tarantino G, Serra V, et al. Liver transplantation and combined hepatocellular-cholangiocarcinoma: Feasibility and outcomes. Dig Liver Dis, 2017, 49: 467-470.
[25] Kim JH Y H, Ko GY, Et A. Nonresectable combined hepatocellular carcinoma and cholangiocarcinoma: analysis of the response and prognostic factors after transcatheter arterial chemoembolization. Radiology, 2010, 255: 270-277.
[26] Fowler K, Saad NE, Brunt E, et al. Biphenotypic primary liver carcinomas: assessing outcomes of hepatic directed therapy. Ann Surg Oncol, 2015, 22: 4130-4137.
[27] Kobayashi S, Terashima T, Shiba S, et al. Multicenter retrospective analysis of systemic chemotherapy for unresectable combined hepatocellular and cholangiocarcinoma. Cancer Sci, 2018, 109: 2549-2557.
[28] Salimon M, Prieux-klotz C, Tougeron D, et al. Gemcitabine plus platinum-based chemotherapy for first-line treatment of hepatocholangiocarcinoma: an AGEO French multicentre retrospective study. Br J Cancer, 2018, 118: 325-330.
[29] Futsukaichi Y, Tajiri K, Kobayashi S, et al. Combined hepatocellular-cholangiocarcinoma successfully treated with sorafenib: case report and review of the literature. Clin J Gastroenterol, 2019, 12: 128-134.
[30] Broutier L, Mastrogiovanni G, Verstegen MM, et al. Human primary liver cancer-derived organoid cultures for disease modeling and drug screening. Nat Med, 2017, 23: 1424-1435.
[31] Jeon J, Maeng LS, Bae YJ, et al. Comparing Clonality Between Components of Combined Hepatocellular Carcinoma and Cholangiocarcinoma by Targeted Sequencing. Cancer Genomics Proteomics, 2018, 15: 291-298.
[32] Maeda TAE, Kajiyama K, Sugimachi K, et al. Combined hepatocellular and cholangiocarcinoma: proposed criteria according to cytokeratin expression and analysis of clinicopathologic features. Hum Pathol, 1995, 26: 956-964.
[33] Lo HC, Lee KF, Yeh CN, et al. Breast metastasis from hepatocellular carcinoma. Hepatogastroenterology, 2004, 51: 387-390.
[34] Sempokuya T, Wien EA, Pattison RJ, et al. Factors associated with 5-year survival of combined hepatocellular and cholangiocarcinoma. World J Hepatol, 2020, 12: 1020-30.
[35] Coussens LM, Werb Z. Inflammation and cancer. Nature, 2002, 420: 860-867.
[36] Zheng BH, Ma JQ, Tian LY, et al. The distribution of immune cells within combined hepatocellular carcinoma and cholangiocarcinoma predicts clinical outcome. Clin Transl Med, 2020, 10: 45-56. |
